135 related articles for article (PubMed ID: 17194383)
1. [Mutant-prevention concentration: a new, clinically relevant parameter of antimicrobial activity?].
Cantón R
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):599-602. PubMed ID: 17194383
[No Abstract] [Full Text] [Related]
2. [Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Sirvent E; Ruiz M; Rodríguez JC; Royo G
Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):603-7. PubMed ID: 17194384
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections.
Rubin J; Walker RD; Blickenstaff K; Bodeis-Jones S; Zhao S
Vet Microbiol; 2008 Sep; 131(1-2):164-72. PubMed ID: 18395369
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of resistance to aminoglycosides and fluoroquinolones among Pseudomonas aeruginosa strains in a University Hospital in Northeastern Poland.
Michalska AD; Sacha PT; Ojdana D; Wieczorek A; Tryniszewska E
Braz J Microbiol; 2014; 45(4):1455-8. PubMed ID: 25763054
[TBL] [Abstract][Full Text] [Related]
5. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
[TBL] [Abstract][Full Text] [Related]
6. Induction of resistance to fluoroquinolones in clinical and environmental isolates of Pseudomonas aeruginosa.
Prasad SV; Ballal M; Shivananda PG
Indian J Pathol Microbiol; 2007 Jan; 50(1):94-6. PubMed ID: 17474274
[TBL] [Abstract][Full Text] [Related]
7. Analysis of resistance, cross-resistance and antimicrobial combinations for Pseudomonas aeruginosa isolates from 1997 to 2009.
Master RN; Clark RB; Karlowsky JA; Ramirez J; Bordon JM
Int J Antimicrob Agents; 2011 Oct; 38(4):291-5. PubMed ID: 21737249
[TBL] [Abstract][Full Text] [Related]
8. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X
Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356
[TBL] [Abstract][Full Text] [Related]
9. Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa.
Cardozo C; Rico V; Agüero D; Soriano A
Rev Esp Quimioter; 2019 Sep; 32 Suppl 2(Suppl 2):32-34. PubMed ID: 31475807
[TBL] [Abstract][Full Text] [Related]
10. [Antibiotic resistance of some Pseudomonas aeruginosa isolates].
Matinca D; Vancea D; Boboş C; Serban O
Bacteriol Virusol Parazitol Epidemiol; 2003; 48(2-3):157-61. PubMed ID: 15341333
[No Abstract] [Full Text] [Related]
11. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections.
Teresa Tejedor M; Martín JL; Navia M; Freixes J; Vila J
Vet Microbiol; 2003 Jul; 94(4):295-301. PubMed ID: 12829383
[TBL] [Abstract][Full Text] [Related]
12. Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Roveta S; Schito AM; Marchese A; Schito GC
Int J Antimicrob Agents; 2005 Nov; 26(5):366-72. PubMed ID: 16216467
[TBL] [Abstract][Full Text] [Related]
13. gyrA and parC mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa from Nini Hospital in north Lebanon.
Salma R; Dabboussi F; Kassaa I; Khudary R; Hamze M
J Infect Chemother; 2013 Feb; 19(1):77-81. PubMed ID: 22821356
[TBL] [Abstract][Full Text] [Related]
14. Comment on "Antimicrobial susceptibility and molecular epidemiological analysis of clinical strains of Pseudomonas aeruginosa".
Arya SC; Agarwal N; Agarwal S
J Infect Chemother; 2008 Dec; 14(6):445-6. PubMed ID: 19089561
[No Abstract] [Full Text] [Related]
15. An outbreak of fluoroquinolone-resistant Pseudomonas aeruginosa ST357 harboring the exoU gene.
Kainuma A; Momiyama K; Kimura T; Akiyama K; Inoue K; Naito Y; Kinoshita M; Shimizu M; Kato H; Shime N; Fujita N; Sawa T
J Infect Chemother; 2018 Aug; 24(8):615-622. PubMed ID: 29628388
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial testing of selected fluoroquinolones against Pseudomonas aeruginosa isolated from canine otitis.
McKay L; Rose CD; Matousek JL; Schmeitzel LS; Gibson NM; Gaskin JM
J Am Anim Hosp Assoc; 2007; 43(6):307-12. PubMed ID: 17975212
[TBL] [Abstract][Full Text] [Related]
17. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
Lei YC; Wang HB; Sun ZY; Shen ZY
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
[TBL] [Abstract][Full Text] [Related]
18. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
Del Barrio-Tofiño E; López-Causapé C; Cabot G; Rivera A; Benito N; Segura C; Montero MM; Sorlí L; Tubau F; Gómez-Zorrilla S; Tormo N; Durá-Navarro R; Viedma E; Resino-Foz E; Fernández-Martínez M; González-Rico C; Alejo-Cancho I; Martínez JA; Labayru-Echverria C; Dueñas C; Ayestarán I; Zamorano L; Martinez-Martinez L; Horcajada JP; Oliver A
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
[TBL] [Abstract][Full Text] [Related]
19. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
Hansen GT; Zhao X; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections.
Hocquet D; Berthelot P; Roussel-Delvallez M; Favre R; Jeannot K; Bajolet O; Marty N; Grattard F; Mariani-Kurkdjian P; Bingen E; Husson MO; Couetdic G; Plésiat P
Antimicrob Agents Chemother; 2007 Oct; 51(10):3531-6. PubMed ID: 17682106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
